| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Experimental Therapeutics and Grace Cancer Drug Center [M. H., E. M.], and Department of Immunology and Immunology Research [T. W., D. P.], Roswell Park Memorial Institute, New York State Department of Health, Buffalo, New York 14203
Growth of Sarcoma 180 in AKR mice was enhanced by immunization with frozen-thawed homogenates of this tumor. Treatment of host mice with rabbit antimyeloma cell antiserum, either during immunization or shortly after tumor implantation, resulted in a decreased incidence of tumor rejection or an increased rate of tumor growth. A slowg-growing subline from a spontaneous DBA/2Ha-DD mammary tumor is rejected after initial growth in DBA/2J mice. The incidence of rejection was reduced by treatment with the antiserum studied.
1 This work was supported in part by USPHS Grants CA-13038 and CA-14562.
2 On leave from the Department of Pathology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan. The work reported in this paper was undertaken during the tenure of a Research Training Fellowship awarded by the International Agency for Research on Cancer.
3 Present address: The Third Department of Internal Medicine, Osaka University Hospital, Osaka, Japan.
Received 9/ 6/74. Accepted 11/21/74.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |